DMC clears Alnylam to continue patisiran Phase III trial

RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) said today that the Data Monitoring Committee (DMC) for the Phase III APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) met on October 7, 2016, and recommended continuation of the trial without modification.

The APOLLO DMC met at the request of the company following the decision – announced on October 5, 2016 – to discontinue development of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). The DMC will continue to meet periodically per their remit to monitor the overall safety of patisiran in the APOLLO study through its completion.

The APOLLO study has completed enrollment of 225 patients at 44 sites in 19 countries, between December 2013 and January 2016. Results of the trial are expected in mid-2017.